Complete Clinical Responders to Definite Chemoradiation in Esophageal Cancer : a Survival Analysis (CRCRT-EC)
February 1, 2012 updated by: Centre Oscar Lambret
Predictors of Survival for Complete Clinical Responders to Definite Chemoradiation or Radiation Therapy for Esophageal Cancer
The aim of this study is to identify prognostic factors for outcome in patients being complete clinical responders with chemoradiation or radiation for esophageal cancer
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
110
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lille, France, 59000
- Centre Oscar Lambret
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patient treated for esophageal cancer in the Northern France Cancer Center from january 1998 to december 2003
Description
Inclusion Criteria:
- localized or locally advanced esophageal cancer
- patient who underwent definite chemoradiation or radiation
- patient with complete clinical response
Exclusion Criteria:
- metastatic disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identification of prognostic factors for overall survival
Time Frame: From date of treatment until death, assessed up to 10 years
|
Correlation between survival and baseline,clinical and treatment characteristics
|
From date of treatment until death, assessed up to 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patterns of treatment failure
Time Frame: From date of treatment until treatment failure, assessed up to 10 years
|
Type of recurrence : local, regional, distant.
|
From date of treatment until treatment failure, assessed up to 10 years
|
|
Disease-free survival
Time Frame: From date of treatment until progression or death, assessed up to 10 years
|
Time between the end of treatment and the occurence of progression
|
From date of treatment until progression or death, assessed up to 10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
January 1, 2012
Study Completion (Actual)
January 1, 2012
Study Registration Dates
First Submitted
January 30, 2012
First Submitted That Met QC Criteria
February 1, 2012
First Posted (Estimate)
February 3, 2012
Study Record Updates
Last Update Posted (Estimate)
February 3, 2012
Last Update Submitted That Met QC Criteria
February 1, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRCRT-EC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.